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ABSTRACT In CHO cells we had found that CCK
positively regulated cell proliferation via the activa-
tion of a soluble guanylate cyclase. Here we demon-
strate that CCK stimulated a nitric oxide synthase
(NOS) activity. The production of NO was involved
in the proliferative response elicited by CCK regard-
ing the inhibitory effect of NOS inhibitors L-NAME
and a-guanidinoglutaric acid. We identified the NOS
activated by the peptide as the neuronal isoform: the
expression of the C415A neuronal NOS mutant
inhibited both CCK-induced stimulation of NOS
activity and cell proliferation. These two effects were
also inhibited after expression of the C459S tyrosine
phosphatase SHP-2 mutant and the bARK1 (495–
689) sequestrant peptide, indicating the requirement
of activated SHP-2 and G-bg subunit. Kinetic analy-
sis (Western blot after coimmunoprecipitation and
specific SHP-2 activity) revealed that in response to
CCK-treatment, SHP-2 associated to G-b1 subunit,
became activated, and then dephosphorylated the
neuronal NOS through a direct association. These
data demonstrate that the neuronal NOS is impli-
cated in proliferative effect evoked by CCK. A novel
growth signaling pathway is described, involving the
activation of neuronal NOS by dephosphorylation of
tyrosyl residues.—Cordelier, P., Este`ve, J.-P., Rivard,
N., Marletta, M., Vaysse, N., Susini, C., Buscail, L.
The activation of neuronal no synthase is mediated
by G-protein bg subunit and the tyrosine phospha-
tase SHP-2. FASEB J. 13, 2037–2050 (1999)
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Cholecystokinin (CCK) is a gastrointestinal regu-
latory hormone originally isolated from the porcine
duodenum as a 33 amino acid peptide. CCK partic-
ipates in a variety of biological processes such as
contraction of the gallbladder, stimulation of the
exocrine and endocrine secretions, inhibition of
gastric emptying, and modulation of gut peristaltism
and trophic effects, notably on pancreas (1). CCK
has also been found to be expressed in brain and in
nerve endings in many parts of the body, and thus
acts as a neuropeptide in both the central and
peripheral nervous systems. In the central nervous
system, the CCK-8 form that possesses the complete
biological activity of CCK is mainly represented and
is involved in behavioral processes such as anxiety or
satiety.
CCK is known to stimulate pancreatic growth in
vitro and in vivo in the mouse, rat, or hamster (2). In
rat exocrine pancreas, this effect has been shown to
be mediated by the CCKA receptor subtype (3, 4). In
this latter cellular model, CCKA receptors interact
with G-proteins (guanine nucleotide binding pro-
teins) and thereby mediate the activation of different
intracellular pathways, leading to 1) the stimulation
of intracellular calcium mobilization (via phospho-
lipase C/inositol phosphate systems), 2) an increase
of cyclic AMP, cyclic GMP (cGMP), arachidonic acid,
and phosphatidic acid levels, and 3) the stimulation
of tyrosine kinase or tyrosine phosphatase activities
(1, 5). However, the mechanism(s) involved in the
proliferative effect induced by CCK through CCKA
receptors is not completely elucidated.
We recently demonstrated that CHO-K1 cells ex-
pressed endogenous CCKA receptors (6). In this
model we also observed that CCK-8 stimulated cell
proliferation. This effect occurred through an acti-
vation of a soluble guanylate cyclase via a pertussis
toxin-sensitive Gi/G0 protein, followed by activation
of the protein kinase G and the MAP kinase system
(6). It represented a new example of a positive effect
of CCK on cell proliferation that is mediated by
CCKA receptors. It was an additional observation of
the positive effect of cGMP on cell proliferation, the
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nucleotide being more frequently responsible for an
inhibition of cell proliferation or migration.
The potent activator of soluble guanylate cyclase is
nitric oxide (NO). NO is a ubiquitous endogenous
messenger molecule that participates in a variety of
physiological and pathophysiological processes. NO
is produced by NO synthases (NOS), which catalyze
the oxidation of L-arginine to form L-citrulline and
NO (7–9). NO synthases constitute at least three
distinct isoforms, which are the products of individ-
ual genes. All catalyze the formation of NO. Two of
these isoforms, neuronal (nNOS) and endothelial
(eNOS) NOS, are constitutively expressed (includ-
ing resting cells) and regulated by Ca21/calmodulin.
The third one is inducible (iNOS) in a number of
cell types, including macrophages, after exposure to
bacterial lipopolysaccharide in conjunction with cy-
tokines that stimulate iNOS protein formation (9).
NO is known to act as a messenger in neuronal
transmission, control of vascular tone, and immune
response-induced cytostasis. It is also implicated in
many other processes such as cerebral blood flow
and ischemia, platelets and neutrophil aggregation,
coronary perfusion, lung ventilation, glomerular
perfusion, endocrine and exocrine secretion of pan-
creas, gut peristaltism and secretion, cell prolifera-
tion, and migration (10).
To further characterize the growth-promoting ef-
fect evoked by CCK-8, we have investigated the
possible involvement of NO, the production of
which could activate the soluble guanylate cylase/
cGMP pathways and subsequently cell proliferation.
Other aims of the study were to identify the NOS
isoform that could be activated by CCK treatment
and the mechanism of activation of this NOS.
MATERIALS AND METHODS
Reagents
Sulfated cholecystokinin-8 (CCK-8) and quinolinequinone
(LY 83583) were purchased from Bachem (Voisin le Breton-
neux, France). [g-33P]ATP (3000 Ci/mmol) was purchased
from Isotopchim (Ganagobie, France). AG50W-X8 resin (so-
dium form) and Polyprep columns were from Bio-Rad (Ivry
sur Seine, France). [14C] L-arginine, enhanced chemilumi-
nescence (ECL) immunodetection system, and Hybond ECL
nitrocellulose membrane were from Amersham Corp (Les
Ulis, France). CHAPS was from Serva (Heidelberg, Ger-
many). Leupeptin, tetrahydro-L-bioptherin (BH4), b-NADPH,
FMN, FAD, NG-nitro-L-arginine (L-NAME), calmodulin, per-
tussis toxin, soybean trypsin inhibitor, poly(Glu, Tyr), choles-
terol hemisuccinate, dithiothreitol (DTT), L-citrulline, L-
arginine, Sepharose-protein A beads, and geneticin (G418)
were from Sigma (Saint Quentin Fallavier, France). a-Gua-
nidinoglutaric acid (GGA) and bovine b1g2 recombinant
protein were from Calbiochem (Meudon, France). Fugene-6
was from Boehringer Mannheim (Meylan, France).
Antibodies
Monoclonal anti-human neuronal NOS, monoclonal an-
tiphosphotyrosine-PY20 antibodies, and monoclonal anti-hu-
man SHP-2 antibody were from Transduction Laboratories
(Montluc¸on, France). Rabbit polyclonal anti-human neuro-
nal NOS antibody was from Biomol (Plymouth, Pa.). Anti-b1
subunit antibody was from Gramsch Laboratories (Schwab-
hoˆusen, Germany). Polyclonal anti-SHP-2 antibody was kindly
provided by Dr. F. McKenzie (CNRS-UMR134, Nice, France).
Cell culture and transfection
CHO cells (CHO K1 strain) were cultured in a-modified
Eagle’s medium (aMEM) containing 10% fetal calf serum
(FCS), fungizone, streptomycin, and penicillin. The bovine
carboxyl-terminal b-adrenergic receptor kinase 1 (bARK1)
(495–689) b-globin fragment cDNA, subcloned in pRK5, was
kindly provided by Drs. M. Lohse and R. Lefkovitz (HHMI,
Duke University Medical Center, Durham, N.C.). Cells were
concomitantly transfected with pRK5-bARK1 and pSV2neo
(Clontech, Palo Alto, Calif.) vectors. Stable transfectants were
selected in aMEM containing geneticin at 600 mg/ml. After
selection, cells were cultured in aMEM containing 10% FCS
and geneticin (200 mg/ml). pSV2neo vector alone stable
transfectants were used as control clones.
The rat heme-deficient neuronal nitric oxide synthase
mutant C415A nNOS was subcloned in pCMV5 vector, kindly
provided by P. Rouet (INSERM U317, Toulouse, France).
The C459S SHP-2 mutant (11) was subcloned in the pcDNA3
vector, a gift from C. Nahmias (ICGM Cochin, Paris). For
transient transfection, CHO cells were grown in 60 mm
diameter dishes for 18 h in aMEM containing 10% FCS. After
aMEM was removed, cells were transfected with 2 mg of
pCMV5/C415A nNOS or 1 mg of pcDNA3/C459S SHP-2
vector and 1 mg of bgal vector containing b-galactosidase
cDNA (kindly provided by H. Paris, INSERM U388, Toulouse,
France), used as transfection internal control, and 6 ml
Fugene-6 in aMEM without FCS for 30 h. b-galactosidase
activity was assayed using o-nitrophenolb-D-galactopyranoside
as substrate. Cells transfected with pCMV5 or pcDNA3 vectors
alone were used as control. In these conditions of transient
transfection, percentage of cell transfected at 30 h was 48 6
4% (mean6se), as measured after transient expression of
green fluorescent protein (driven by the CMV promoter) and
analysis under microscope (image-analysis system Viso-Lab
2000, Biocom, Paris, France).
NO synthase activity
CHO cells were plated in 60 mm diameter dishes at 50 3 103
cells/ml (5 ml of aMEM containing 10% FCS per dish) until
subconfluence and, after an 18 h period of serum depriva-
tion, were treated with CCK-8 with or without other agents
tested. Cells were then homogenized using a Dounce homog-
enizer (60 strokes at 4°C) in 50 mM Tris buffer (pH 7.5)
containing 0.1 mM EDTA, 0.1 mM EGTA, 10% glycerol, 20
mM leupeptin, 1 mM PMSF, 1 mM soybean trypsin inhibitor,
0.1% CHAPS. Protein was assayed using the Bio-Rad Reagent
and 25 mg of cell proteins were then incubated for 15 min at
37°C in 50 mM Tris buffer (pH 7.4) containing 50 mM
[14C]L-arg (150,000 cpm, specific activity 58.7 Ci/mmol), 10
mM bNADPH, 1 mM DTT, 4 mM FMN, 4 mM FAD, 10 mM
BH4, 2 mg of calmodulin, and 1 mM CaCl2 in a final
incubation volume of 200 ml. The reaction was terminated by
addition of 1 ml of quench buffer containing 20 mM HEPES,
2 mM EDTA, 0.2 mM EGTA, 1 mM L-citrulline. The samples
were applied to 2 ml columns of Dowex AG50W-X8 (Na1
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form) preequilibrated with quench buffer. Columns were
then eluted with 2 ml of quench buffer and radioactivity in
the eluates was measured by liquid scintillation.
Cell growth assay
CHO cells were cultured in aMEM containing 10% FCS and
plated in 35 mm dishes at 50 3 103 cells/ml (2 ml per dish).
After an overnight attachment phase, the medium was
changed to aMEM containing either 10% FCS or 0% FCS,
with or without other different agents tested. Cell growth was
measured after 24 h by cell counting with a Coulter counter
model ZM, as described previously (12). Cell growth assays
using treatment with exogenous L-arginine were performed
in L-arginine-free aMEM.
SHP-2 activity assay
CHO cells were plated in 100 mm diameter dishes at 100 3
103 cells/ml for 16 h (10 ml of aMEM containing 10% FCS
per dish) until subconfluence; after an 18 h period of serum
deprivation, they were treated with CCK-8 or other agents.
CHO and CHO/bARK1 cells were washed twice with phos-
phate-buffered saline (PBS) and solubilized for 10 min on ice
with 50 mM Tris buffer (pH 7.6) containing 140 mM NaCl, 5
mM MgCl2, 5 mM sodium orthovanadate, and 0.05% soybean
trypsin (buffer A) in the presence of 1.5% CHAPS and 0.5
mg/ml cholesterol hemisuccinate. The mixture was gently
agitated for 30 min at 4°C and centrifuged at 13,000 3 g for
20 min. Soluble proteins (100 mg) were incubated for 2 h at
4°C with anti-SHP-2 or preimmune serum prebound to
Sepharose-protein A beads prewashed in buffer A in the
presence of 0.1% CHAPS, 60 mg/ml cholesterol hemisucci-
nate, and 0.3% bovine serum albumin. Immunoprecipitated
proteins were then washed once with 40 mM Tris buffer (pH
7) containing 0.5 mM EDTA, 0.1% Tween 20, and 0.1%
sodium dodecyl sulfate (SDS), resuspended in 380 ml of the
same buffer, and duplicated for tyrosine phosphatase assay.
The substrate poly-(Glu, Tyr) was phosphorylated with
[g-33P]ATP as described previously (13). Dithiothreitol (5
mM) was added; the reaction was initiated by the addition of
30,000 cpm of 33P-labeled poly(Glu, Tyr) and allowed to
proceed for 10 min at 30°C. PTPase activity was assayed as
described previously (12) and expressed in picomoles of
inorganic phosphate released per minute at 30°C from radio-
labeled substrate.
Immunoprecipitation and immunoblotting
CHO cells were plated in 100 mm diameter dishes at 100 3
103 cells/ml (10 ml per dish) until subconfluence, and after
an 18 h period of serum deprivation were treated with CCK-8,
with or without other agents tested. CHO cells were washed
twice in PBS and solubilized for 10 min on ice with 50 mM
Tris buffer (pH 7.6) containing 140 mM NaCl, 1 mM EDTA,
0.05% soybean trypsin inhibitor, and 0.1 mM phenylmethyl-
sulfonyl fluoride (buffer A) in the presence of 1.5% CHAPS
and 0.5 mM sodium orthovanadate. The mixture was gently
agitated for 30 min at 4°C and centrifuged at 13,000 3 g for
20 min. Soluble proteins (500 mg to 1 mg) were incubated for
3 h at 4°C with antiphosphotyrosine or anti-nNOS, or anti-
SHP-2 antibodies or preimmune serum prebound to Sepha-
rose-protein A beads prewashed in buffer A. The beads were
then washed twice with buffer A and resuspended in 50 ml of
Laemmli buffer 3% SDS.
For immunoblotting, 50 ml of immunoprecipitated pro-
teins (see above) or 50 mg of solubilized proteins were
resolved through 7.5% or 12% SDS-polyacrylamide gels,
transferred to a nitrocellulose membrane, and immunoblot-
ted with anti-human nNOS, anti-PY20, anti-b1 subunit, or
anti-SHP-2 antibodies. Immunoreactive proteins were visual-
ized by the ECL immunodetection system and quantified by
image analysis using a Biocom apparatus.
For visualization of monomers and dimers of nNOS, low-
temperature SDS-polyacrylamide gels were performed.
Briefly, cells treated or not with CCK-8 and transfected or not
with the mutant nNOS cDNA were solubilized for 30 min at
4°C in a Tris 50 mM buffer (pH 7.6) containing 140 mM
NaCl, 5 mM MgCl2, 0.5 mM ortho-vanadate, 0.05% soybean
trypsin inhibitor, and 0.1 mM phenylmethylsulfonyl fluoride
in the presence of 1% CHAPS and 10% glycerol. After
addition of Laemmli buffer 3% SDS without b-mercaptoetha-
nol or heating, 100 mg of solubilized proteins was resolved
through discontinuous 5% to 15% SDS-polyacrylamide gradi-
ent gels performed at a constant current of 30 mA. Gels and
buffers were equilibrated at 4°C prior to electrophoresis,
which was performed at temperature below 15°C, as de-
scribed previously (14). Immunoblotting was performed as
described above using anti-human nNOS antibodies.
RESULTS
Nitric oxide production is involved in the growth
signaling pathway of CCK
CCK-8 stimulated the proliferation of CHO-K1 cells
in a dose-dependent manner, with a maximal effect
observed at a concentration of 0.1 mM. This effect
occurred through an activation of a soluble guany-
late cyclase (6). NO is the activator of soluble guan-
ylate cyclase. To further characterize this effect,
CHO-K1 cells were treated or not with 0.1 mM CCK-8
for different times. As shown in Fig. 1A, NOS activity
was stimulated in a time-dependent manner, with a
maximal effect after 30 s of CCK treatment, followed
by a decrease until 5 min. As shown in Fig. 1B, an
18 h pretreatment of cells with 100 ng/ml of pertus-
sis toxin reduced by 79 6 4% the CCK-induced
stimulation of NOS activity.
To investigate the role of NO production on cell
proliferation caused by CCK, CHO cells cultured in
serum-free medium were treated with the NO donor
sodium nitroprusside (1 nM to 1 mM). This treat-
ment resulted in a dose-dependent increase of cell
proliferation when compared to control cells cul-
tured in serum-free medium, maximal effect being
observed at 0.1 mM sodium nitroprusside (SNP;
13869%, ED50: 1.2260.4 nM) (data not shown
from three experiments performed in triplicate).
Treatment of cells with the substrate of NOS L-
arginine (100 mM), resulted also in an increase of
cell proliferation when compared to control cells
(Fig. 2). We also observed that cell proliferation
induced by 0.1 mM SNP was inhibited by 57 6 1%
when cells were concomitantly treated with the sol-
uble guanylate cyclase inhibitor LY 83583 (0.1 mM)
(Fig. 2).
To further characterize the possible involvement
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of NO production in the proliferative effect evoked
by CCK, CHO cells were treated for 24 h with 0.1 mM
CCK-8 in the presence or not of the inhibitors of
NOS L-NAME and GGA. As shown in Fig. 2, CCK-
induced CHO cell proliferation was inhibited by
incubating cells with the two inhibitors. These inhib-
itors had no effect on the basal cell proliferation
(data not shown). No additive effect could be ob-
served on cell proliferation when cells were concom-
itantly treated with CCK-8 (0.1 mM) and L-arginine
(100 mM), indicating that the same pathway was
involved. Taken together, these results indicate that
CCK stimulated CHO cell proliferation through the
activation of a NOS and by a mechanism involving a
pertussis-toxin-sensitive Gi/G0 protein.
The constitutive nNOS is involved in the growth
signaling pathway of CCK
In CHO cells, the conditions and the kinetics of
activation of NOS activity were consistent with the
involvement of a constitutive NOS isoform. As de-
scribed previously (15), immunoblotting revealed
that CHO-K1 cells expressed endogenous constitu-
Figure 2. Nitric oxide is involved in proliferation of CHO-K1
cells. CHO cells were plated in aMEM containing 10% FCS
until subconfluence; cell proliferation was induced in serum-
free medium by a 24 h treatment with CCK-8. Concomitant
with the CCK-8 treatment, cells were treated with the NO
synthase inhibitors L-NAME and a-guanidinoglutaric acid
(GGA). Cells were also treated for 24 h with the NO synthase
substrate, L-arginine, or the NO donor sodium nitroprusside
(SNP) with or without LY 83583 (0.1 mM). Cell proliferation
was evaluated by cell counting, results are expressed as the
percentage of control values obtained with CCK-treated cells.
Treatment with L-arginine was performed in arginine-free
medium. When given alone, LY 83583 had no effect on basal
cell proliferation. Under these conditions, 0.1 mM CCK-8
induced stimulation of cell proliferation 45 6 4% above
basal values observed for cells grown in FCS-free medium
(mean6se of three experiments performed in triplicate).
Figure 1. CCK activates NO synthase activity through a
pertussis toxin-dependent mechanism in CHO-K1 cells. A)
CHO-K1 cells were plated in aMEM containing 10% FCS
until subconfluence and were treated after an 18 h period of
serum deprivation with 0.1 mM CCK-8 for 5 min at 37°C. NOS
activity was assayed on cell homogenates at the times indi-
cated by measuring the conversion of L-arginine 14C into
L-citrulline. Results are expressed in percent of control value
(1.360.2 pmol of citrulline produced/mg of protein per
minute) obtained for untreated cells at time 0 (mean6se of
three experiments in duplicate). B) CHO-K1 cells were plated
in aMEM containing 10% FCS until subconfluence and
treated, after an 18 h period of serum deprivation, with 0.1
mM CCK-8 for 30 s at 37°C after (hatched bars) or without
(open bars) a 24 h preincubation of cells with 100 ng/ml of
pertussis toxin. Results are expressed in pmol of citrulline
produced/mg of protein per minute and are the mean 6 se
of three experiments in duplicate.
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tive nNOS (Fig. 3A). However, we also detected the
endothelial NOS isoform by Western blotting, this
isoform being expressed less than nNOS (data not
shown). In addition, we found that the NOS inhibi-
tor GGA abolished the CCK-induced stimulation of
both cell proliferation and NOS activity in CHO
cells. This inhibitor, also known to be an anticonvul-
sant compound, is highly active in neuronal tissues
that predominantly express nNOS. To obtain direct
evidence that nNOS was activated by CCK in CHO
cells and that this isoform was implicated in the
positive effect of CCK on CHO cell proliferation, we
transiently expressed the rat C415A nNOS mutant
(Cys415 mutated to Ala). This mutant does not bind
heme and tetrahydrobiopterin, essential cofactors
required for NO synthesis (16, 17). After transient
expression of the C415A nNOS mutant, immuno-
blotting demonstrated expression of two forms of
nNOS (Fig. 3A) in cells transfected with the pCMV5/
C415A nNOS vector when compared to cells trans-
fected with the pCMV5 control vector alone. The 155
kDa form corresponds to the recombinant rat iso-
form and the 160 kDa form to the endogenous
hamster nNOS form, also detected in the hamster
cerebellum soluble extracts used as positive control.
As shown in Fig. 3B, CCK-8 was unable to stimulate
NOS activity in CHO cells transiently expressing the
nNOS mutant when compared to cells transiently
transfected with the pCMV5 vector alone. In addi-
tion, CCK-8 could not induce cell proliferation in
cells expressing the nNOS mutant (Fig. 3B, insert).
To investigate the effect of C415A nNOS mutant,
solubilized cells transfected with pCMV5/C415A
nNOS or pCMV5 vectors were subjected to low-
temperature SDS-polyacrylamide gel electrophoresis
(PAGE) in order to evaluate the amount of dimeric
Figure 3. The constitutive nNOS is implicated in the regulation of cell proliferation evoked by CCK in CHO cells. A) CHO cells were
transiently transfected with 2 mg of pCMV5 control vector and/or 2 mg of pCMV5/C415A nNOS vector containing the C415A rat
nNOS mutant. After a 24 h expression, cells were treated or not with 0.1 mM CCK-8 at 37°C for 30 s and solubilized with 1.5% CHAPS.
The lysates were then resolved by 7.5% SDS-PAGE and analyzed by immunoblotting with the anti-nNOS antibody. Lanes 1 and 2
correspond to pCMV5-expressing cells (1: untreated; 2: treated); lanes 3 and 4 correspond to pCMV5/C415A nNOS-expressing cells
(3: untreated; 4: treated); lane 5 corresponds to solubilized proteins from Syrian golden hamster cerebellum, used as a positive
control. Results are representative of two immunoblots each performed after different sets of cell transfection. B) CHO cells were
transiently transfected with the pCMV5 control vector (open bars) or the pCMV5/C415A nNOS vector (hatched bars). Each vector
was cotransfected with 1 mg of PGL3/bGAL vector in order to standardize results and to take into account the yield and rate of
transient transfection. After 24 h expression, cells were treated or not with 0.1 mM CCK-8 at 37°C for 30 s and NOS activity was
measured on cell homogenates. Results are expressed in NOS/b-galactosidase activity and are the mean 6 se of three separate
experiments in duplicate. Insert: CHO cells were transiently transfected with the pCMV5 control vector (open bars) or the
pCMV5/C415A nNOS mutant (hatched bars). After a 24 h expression, cells were treated or not with 0.1 mM CCK-8 for 24 h and cell
proliferation was evaluated by cell counting. Results are expressed as the percentage of control values obtained in untreated cells
cultured in serum-free medium and are the mean 6 se of three separate experiments performed in triplicate. C) CHO cells were
transiently transfected with the pCMV5/C415A nNOS mutant (lanes 1, and 2) or the pCMV5 control vector (lanes 3, and 4). After
24 h expression, cells were treated or untreated with 0.1 mM CCK-8 at 37°C for 30 s and solubilized with 1% CHAPS. The lysates were
then resolved by low temperature through 5–15% SDS-polyacrylamide discontinuous gradient gel and analyzed by immunoblotting
with the anti-nNOS antibody (nNOS: 155–160 kDa monomeric forms of both wild-type and mutant nNOS; di-NOS: 320 kDa dimeric
nNOS form). A longer exposition of films with ECL detection revealed the presence of 160 kDa bands in lanes 3 and 4 corresponding
to the wild-type endogenous nNOS (data not shown). Results are representative of three immunoblots, each performed after different
sets of cell transfection and CCK treatment.
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nNOS (320 kDa) relative to monomeric nNOS (155–
160 kDa). As shown in Fig. 3C (lanes 1 and 3), the
amount of nNOS dimers was not increased after
expression of the nNOS mutant when compared to
the control cells. In addition, under CCK treatment,
the amount of endogenous nNOS dimers was in-
creased (lane 4) in control CHO cells. This increase
was abolished after nNOS mutant expression (lane
2). All these results suggest that CCK can induce
endogenous nNOS dimerization. This effect is pre-
vented after transfection of inactive nNOS without
apparent heterodimerization between endogenous
nNOS and heterologous mutant nNOS.
SHP-2 mediates the stimulation the nNOS activity
and cell proliferation induced by CCK
The activity of the constitutive NOS isoforms such as
nNOS is critically controlled by an elevated level of
intracellular calcium, which promotes binding of
calmodulin to the enzymes. In CHO-K1 cells, we
previously demonstrated that CCK can induce mobi-
lization of intracellular calcium (12). However, this
effect appeared to be pertussis toxin independent,
and calcium mobilization was not implicated in the
proliferative effect of CCK in these cells (6). Evi-
dence exists that endothelial isoform of NOS could
be activated by pathways other than the increase of
intracellular calcium concentrations, such as by
phosphorylation or dephosphorylation of proteins
on tyrosine or serine-threonine residues (18). Previ-
ous reports demonstrated that CCK activated ty-
rosine kinase and tyrosine phosphatase activities,
and these effects could be involved in the trophic
effect of CCK in vivo (5).
We first tested the possible implication of a ty-
rosine phosphatase activity in the CCK-induced cell
proliferation. CHO cells were concomitantly treated
or not for 24 h with CCK-8 and the tyrosine phos-
phatase inhibitor pervanadate. At concentrations of
0.1, 0.3, and 0.5 mM, pervanadate inhibited CCK-
induced cell proliferation (27268.5% at 0.3 mM)
(Fig. 4). The basal cell proliferation of CHO-K1 was
not affected at these three concentrations, but was
inhibited at 1 mM of pervanadate (data not shown).
In parallel, we tested the effect of okadaic acid, the
inhibitor of the serine threonine phosphatases,
which had no effect on CCK-induced cell prolifera-
tion at a concentration of 0.1 mM (data not shown
from three experiments performed in triplicate). All
these results suggested that CCK-induced cell prolif-
eration depends on the activation of a tyrosine
phosphatase.
The phosphotyrosine phosphatase SHP-2 is a pos-
itive mediator of the mitogenic signaling induced by
several growth factors (19). To determine whether
CCK activated the tyrosine phosphatase SHP-2 in
CHO cells, cells were incubated in the presence of
CCK-8 for various times (after which they were
solubilized) and SHP-2 activity was measured in
SHP-2 immunoprecipitates. As shown in Fig. 5, treat-
ment by CCK evoked a rapid and time-dependent
stimulation of SHP-2 activity. The stimulation of
SHP-2 activity was maximal after 1 min of CCK
treatment and declined for up to 15 min.
To obtain direct evidence that tyrosine phospha-
tase SHP-2 was implicated in the positive effect of
CCK on CHO cell proliferation, we transiently ex-
pressed the dominant negative mutant SHP-2
(C459S mutant: Cys459 mutated to serine) (11). After
transient expression of the mutant, immunoblotting
with anti-SHP-2 antibodies demonstrated that ex-
pression of the protein in cells (treated or untreated
with CCK-8) transfected with pcDNA3/C459S SHP-2
vector was increased when compared to cells trans-
fected with pCDNA3 vector alone (Fig. 6A). This
increase may correspond to the recombinant mutant
transiently expressed in CHO cells. After transient
expression of the SHP-2 mutant, CCK-8 was unable
to stimulate cell proliferation when compared to
cells transiently transfected with the pcDNA3 control
vector alone (Fig. 6B). As shown in Fig. 6B (insert),
the inhibition of CCK-8-induced cell proliferation
depended on the concentration of the pcDNA3/
C459S SHP-2 plasmid transfected, maximal effect
being observed with 1.5–2 mg.
To determine whether the NOS activity stimulated
by CCK depends on a tyrosine phosphatase activa-
tion, CHO cells were treated or untreated with
Figure 4. A tyrosine phosphatase is implicated in the CCK-
induced cell proliferation of CHO cells. CHO cell prolifera-
tion was induced by a 24 h treatment with 0.1 mM CCK-8.
Cells were concomitantly treated or not with the tyrosine
phosphatase inhibitor pervanadate at the concentrations in-
dicated. Cell proliferation was measured by cell counting and
results are expressed as the percentage of control values
obtained with control untreated cells cultured in serum-free
medium (mean6se of three experiments performed in trip-
licate).
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CCK-8 for 30 s after or without a 15 min preincuba-
tion with pervanadate at a concentration of 0.3 mM.
As shown in Fig. 7A, pretreatment of cells with
pervanadate had no effect on basal NOS activity, but
inhibited by 90 6 1% the CCK-induced stimulation
of NOS activity, suggesting that activation of NOS
depends on the activation of a tyrosine phosphatase.
To ask whether CCK regulates the level of tyrosine
phosphorylation of nNOS, CCK-treated or untreated
CHO cells were subjected to immunoprecipitation
with antiphosphotyrosine antibodies. Immunoblot
with anti-nNOS antibodies revealed that nNOS of
untreated cells was tyrosine phosphorylated and rap-
idly dephosphorylated after CCK treatment, maxi-
mal dephosphorylation being observed at 15 and
30 s, which slowly decreased until 5 min. Pretreat-
ment of cells with 0.3 mM pervanadate for 15 min
inhibited nNOS tyrosine dephosphorylation induced
by a 30 s CCK treatment (Fig. 7B, D). In addition,
converse experiments revealed that a similar profile
and kinetic of nNOS dephosphorylation under CCK
treatment were observed after immunoprecipitation
of CHO cells with anti-nNOS antibodies, followed by
immunoblot with antiphosphotyrosine antibodies
(Fig. 7C).
To obtain evidence that CCK may activate a NOS
activity in CHO cells by stimulating SHP-2, we tran-
siently expressed the inactive SHP-2 C459S mutant
(immunoblotting of transfected cells with anti-SHP-2
antibodies is shown in Fig. 8A). After transient
expression of this mutant, CCK-8 was unable to
stimulate NOS activity when compared to cells tran-
siently transfected with the pcDNA3 control vector
alone (Fig. 8B). As shown in Fig. 8C, dephosphory-
Figure 5. CCK stimulates SHP-2 activity in CHO cells. CHO
cells were plated in aMEM containing 10% FCS until subcon-
fluence and after an 18 h period of serum deprivation were
treated or not with 0.1 mM CCK-8 for the indicated times
prior to solubilization and immunoprecipitation with the
anti-SHP-2 antibodies. Immunoprecipitates were assayed for
tyrosine phosphatase activity in the presence of 33P-labeled
poly(Glu, Tyr). Results are expressed in pmol/min and are
the mean 6 se of four experiments in duplicate.
Figure 6. The tyrosine phosphatase SHP-2 is implicated in the
regulation of cell proliferation evoked by CCK in CHO cells.
A) CHO cells were transiently transfected with 1 mg of
pCDNA3 control vector or 1 mg of pCDNA3/C459S SHP-2
vector containing the human C459S SHP-2 mutant. After
24 h expression, cells were treated or not with 0.1 mM CCK-8
for 30 s at 37°C, and solubilized with 1.5% CHAPS. The
lysates were then resolved by 7.5% SDS-PAGE and analyzed
by immunoblotting with the anti-SHP-2 antibody. Lanes 1
and 2 correspond to pCDNA3-expressing cells (1: untreated;
2: treated); lanes 3 and 4 correspond to pCDNA3/C459S
SHP-2-expressing cells (3: untreated; 4: treated). Results are
representative of two immunoblots, each performed after
different sets of cell transfection. B) CHO cells were transiently transfected with 1 mg of pcDNA3 control vector (open bars) or
1 mg of pCDNA3/C459S SHP-2 vector (hatched bars). After a 24 h expression, cells were treated or not with 0.1 mM CCK-8 for
24 h and cell proliferation was assayed by cell counting. Results are expressed in percentage of control values obtained with
untreated cells cultured in serum-free medium and are the mean 6 se of three separate experiments performed in triplicate.
Insert: CHO cells were transiently transfected with increasing concentrations of pCDNA3/C459S SHP-2 vector (hatched bars)
or 1 mg of pCDNA3 control vector (open bars), and treated with 0.1 mM CCK-8 for 24 h; cell proliferation was assayed by cell
counting. Results are expressed in percentage of control values obtained with CCK-treated cells. (results are the mean6se of
three experiments performed in triplicate).
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lation of nNOS induced by CCK-8 treatment of CHO
cells (lanes 1 and 2) was abolished after transfection
of inactive SHP-2 mutant, the basal phosphorylation
of nNOS remaining unchanged (lanes 3 and 4).
These results indicate that activation of SHP-2 is
implicated in the activation of NOS activity and
nNOS dephosphorylation induced by CCK in CHO
cells.
The Gbg subunit complex is involved in the
coupling of CCK receptor to nNOS
Whereas it was thought that Ga was the sole or major
activator of effectors, it is now recognized that Gbg is
also an important independent activator of many dif-
ferent effectors of G-protein actions (including Gi
proteins) (20). To investigate the implication of Gbg in
the CCK-induced activation of NOS, CHO cells were
first treated or not with exogenous Gb1g2 subunit at
final concentrations of 50, 100, and 150 nM under the
same conditions used for CCK-8 treatment. As shown
in Fig. 9A, treatment of solubilized CHO cells with the
exogenous Gb1g2 subunit evoked a stimulation of NO
synthase activity. The maximal effect was observed at a
concentration of 100 nM, the stimulatory effect being
similar to that observed after CCK-8 treatment of
wild-type CHO cells or CHO cells stably expressing the
neomycin-resistant gene alone.
Figure 7. Activation of nNOS by CCK on CHO cells involves a tyrosine phosphatase. A) CHO cells were plated in aMEM
containing 10% FCS until subconfluence and treated after an 18 h period of serum deprivation with 0.1 mM CCK-8 for 30 s at
37°C after (hatched bars) or without (open bars) pretreatment with 0.3 mM of pervanadate for 15 min. Results are expressed
in pmol of citrulline produced/mg of protein per minute (mean6se of three experiments in duplicate). B) CHO cells were
plated in aMEM containing 10% FCS until subconfluence and (after an 18 h period of serum deprivation) treated or not for
indicated times at 37°C with 0.1 mM CCK-8. Cells were concomitantly preincubated or not with 0.3 mM pervanadate (Per-VO4
2-)
for 15 min before a 30 s CCK-8 treatment, then solubilized in 1.5% CHAPS. Cell lysates were subjected to immunoprecipitation
(i.p.) with antiphosphotyrosine antibodies. Immunoprecipitates were resolved by a 7.5% SDS-PAGE and analyzed by
immunoblotting with anti-nNOS antibodies (blot: nNOS). Results are representative of three immunoblots performed in three
separate experiments. C) CHO cells were plated and treated as described in panel B and solubilized in 1.5% CHAPS. Cell lysates
were subjected to immunoprecipitation (i.p.) with anti-nNOS antibodies. Immunoprecipitates were resolved by a 7.5%
SDS-PAGE and analyzed by immunoblotting with antiphosphotyrosine antibodies (blot: P-Tyr). Results are representative of two
immunoblots performed in two separate experiments. D) Immunoblots were densitometrically analyzed and data were plotted
as a percentage of control values obtained from cells at time 0 (open bars: CCK treatment/i.p. P-Tyr/blot: nNOS; hatched bars:
treatment with CCK after preincubation with pervanadate/i.p. P-Tyr/blot nNOS). Data from three separate experiments are
represented as mean 6 se
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The G-protein receptor kinases are known to
phosphorylate multiple receptor serine and threo-
nine residues. Among this kinases, the b-adrenergic
receptor kinases 1 and 2 translocate to a variety of
G-protein-coupled receptors by forming a complex
with the Gbg released upon activation of heterotri-
meric G-proteins. A 125 amino acid domain at the
carboxyl terminus of these kinases provides the
binding site for Gbg. Expression of a minigene
corresponding to the carboxyl terminus amino acid
sequence of bARK1 has been shown to act as a
sequestrant sequence for Gbg subunits when ex-
pressed in COS cells (21). To demonstrate the
implication of Gbg in the CCK-induced stimulation
of both CHO cell proliferation and NOS activity, the
cDNA encoding the carboxyl-terminal 195 amino
acids of the bovine bARK1-(495–689) polypeptide
were stably transfected in CHO cells. Cellular expres-
sion of the minigene product could be demonstrated
by immunoblotting of solubilized cells, using a spe-
cific antibody raised against the last 221 amino acids
of the carboxyl terminus domain of the rat bARK2
(kindly provided by C. Stone, Duke University Med-
ical Center), which recognizes the isoforms bARK-1
and bARK-2, as well as the minigene bARK1 (495–
689) (20). An immunoreactive protein of 28 kDa was
detected in CHO cells expressing bARK1 (495–689),
but not in control CHO cells expressing a neoresis-
tance gene (data not shown). In addition, no effect
was observed on the apparent expression of CCK
receptor (assayed by CCK ligand binding, as de-
scribed in 6) in CHO cells stably expressing the
bARK1-(495–689) polypeptide when compared to
wild-type CHO cells or CHO cells stably expressing
the neomycin resistance gene (data not shown).
As shown in Fig. 9A, B, in cells expressing the
sequestrant polypeptide, CCK-induced stimulation
of NOS activity and cell proliferation were both
abolished. In this clone, the basal NOS remained
unchanged and cell proliferation could be induced
by serum. Similar results were observed in another
clone of CHO cells expressing bARK1-(495–689)
carboxyl-terminal polypeptide (data not shown).
Moreover, treatment of CHO cells stably expressing
Figure 8. Activation of NOS activity by CCK involves the protein-tyrosine phosphatase SHP-2: A) CHO cells were transiently
transfected with 1 mg of pCDNA3 control vector or 1 mg of pCDNA3/C459S SHP-2 vector containing the human C459S SHP-2
mutant. After 24 h expression, cells were treated or not with 0.1 mM CCK-8 for 30 s at 37°C and solubilized with 1.5% CHAPS.
The lysates were then resolved by 7.5% SDS-PAGE and analyzed by immunoblotting with the anti-SHP-2 antibody. Lanes 1 and
2 correspond to pCDNA3-expressing cells (1: untreated; 2: treated); lanes 3 and 4 correspond to pCDNA3/C459S
SHP-2-expressing cells (3: untreated; 4: treated). Results are representative of two immunoblots, each performed after different
sets of cell transfection. B) CHO cells were transiently transfected with the pcDNA3 control vector (open bars) or with the
pCDNA3/C459S vector (hatched bars) containing the C459S human SHP-2 mutant, as described in Materials and Methods.
Each vector was cotransfected with 1 mg of PGL3/bGAL vector. After 24 h expression, cells were treated or not with 0.1 mM
CCK-8 at 37°C for 30 s and NOS activity was measured on cell homogenates. Results are expressed in NOS/b-galactosidase
activity and are the mean 6 se of four separate experiments in duplicate. C) CHO cells were transiently transfected with 1 mg
of pCDNA3 control vector or with 1 mg of pCDNA3/C459S SHP-2 vector containing the human C459S SHP-2 mutant. After 24 h
expression, cells were treated not with 0.1 mM CCK-8 for 30 s at 37°C. After CCK treatment, cells were solubilized in 1.5%
CHAPS. Cell lysates were subjected to immunoprecipitation (i.p.) with antiphosphotyrosine antibodies. Immunoprecipitates
were resolved by a 7.5% SDS-PAGE and analyzed by immunoblotting with anti-nNOS antibodies (blot: nNOS). Lanes 1 and 2
correspond to pCDNA3-expressing cells (1: untreated; 2: treated); lanes 3 and 4 correspond to pCDNA3/C459S SHP-2-
expressing cells (3: untreated; 4: treated). Results are representative of two immunoblots performed after different sets of cell
transfection.
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the bARK1-(495–689) polypeptide with CCK-8 (0.1
mM) did not induce stimulation of SHP-2 activity
whenever the time of treatment (data not shown
from two experiments in duplicate). These results
suggest that in CHO cells, CCK stimulated cell
proliferation, NOS activity, and SHP-2 activity via a
Gbg-dependent pathway.
SHP-2 associates with G-bg subunits and nNOS in
response to CCK treatment
To further characterize the implication of G-bg,
SHP-2, and nNOS in the growth signal evoked by
CCK, CHO cells were either treated not with CCK for
various times prior to solubilization and immunopre-
cipitation with anti-SHP-2 antibodies. The amounts
of G-b1 subunits (always dynamically associated with
the g subunit) and nNOS were then analyzed by
immunoblotting. The blots were reprobed with anti-
SHP-2 antibodies to ensure that comparable
amounts of SHP-2 molecules were immunoprecipi-
tated at each time point of CCK treatment. As
observed in Fig. 10A, the b1 subunit was immuno-
precipitated with SHP-2 antibodies in resting cells.
The treatment with CCK resulted in a rapid increase
of the amount of b1 subunit immunoprecipitated,
which was maximal after 15 and 30 s of treatment
(315645% of control) and decreased until 5 min. In
parallel, we observed that nNOS was also immuno-
precipitated with SHP-2 antibodies in resting cells. In
response to CCK treatment, the amount of immuno-
precipitated nNOS was increased by 240%, with a
maximum observed after 1 min of CCK treatment
and followed by a decrease after 2 and 5 min. The
kinetics of association of nNOS with SHP-2 was
shifted in time when compared to the association of
G-b1 with SHP-2.
DISCUSSION
CCK stimulates cell proliferation of CHO cells
through the activation of neuronal NOS
We first observed that CCK induced a rapid activa-
tion of NO synthase activity. This activation occurred
rapidly, with a maximal effect observed at 30 s of
CCK treatment. This kinetic profile fit well with that
of guanylate cyclase activation, which occurred after
2 min of CCK treatment, before subsequent activa-
tion of MAP kinase activity at 5–10 min. Moreover,
the stimulation of NO synthase by CCK depended on
a pertussis toxin-sensitive pathway, as previously ob-
served for CCK-induced both cell proliferation and
increase of intracellular concentrations of cGMP. We
also demonstrated that both NO synthase substrate
L-arginine and the NO donor sodium nitroprusside
can stimulate CHO cell proliferation, indicating that
endogenous and exogenous production of NO
could stimulate CHO cell proliferation as did exog-
enous and endogenous cGMP (6). The effect of LY
Figure 9. NO synthase activation evoked by CCK-8 required
the Gbg protein subunit. A) CHO-K1 cells expressing the
neomycine resistance gene (open bars) were cultured in
serum-free aMEM and treated or untreated (0) with 0.1 mM
CCK-8 and 100 nM of the b1g2 recombinant peptide for 30 s
at 37°C. In parallel, CHO cells stably expressing the bovine
bARK1-(495–689) polypeptide) (hatched bars) were also
treated or untreated (0) in the same conditions with 0.1 mM
CCK-8 for 30 s at 37°C. NOS activity was measured on cell
homogenates. Results are expressed in pmol of citrulline
produced/mg of protein per minute and are the mean 6 se
of three experiments in duplicate. B) Proliferation of CHO
cells stably expressing the bovine bARK1-(495–689) polypep-
tide) (hatched bars) was induced by a 24 h treatment of
CCK-8 (0.1 mM) and 10% FCS. Cell proliferation was mea-
sured by cell counting. Results are expressed as the percent-
age of control values obtained with untreated cells grown in
FCS-free medium (0) (mean6se of three separate experi-
ments performed in triplicate).
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83583 suggests that NO acts through the activation
of guanylate cyclase and the production of cGMP.
Besides VIP, neurotensin, angiotensin, or musca-
rinic receptors (14, 22), CCKA receptor represents a
novel example of G-protein-coupled receptor that
can be positively coupled to a NOS activity. However,
to our knowledge this is the first report demonstrat-
ing that this positive coupling is implicated in cell
growth stimulation. NO has been shown to inhibit
cell proliferation and cell migration and to induce
apoptosis. However, it has also been shown to pro-
mote proliferation of various cell types in vitro and to
facilitate tumor growth and neovascularization in
vivo (23, 24). Effects of NO on cell proliferation are
known to depend on concentration of the mole-
cule—high concentrations often exerting negative
effects and low concentrations evoking a positive
effect (25). The results we obtained with low concen-
trations of sodium nitroprusside on CHO cells and a
low amount of intracellular NO produced under
CCK treatment correlated well with these observa-
tions.
In the present work, the rapid activation of NOS
activity suggested the involvement of a constitutive
NOS. Moreover, CCK treatment promoted the for-
mation of nNOS dimers, which appear to be the
active form of nNOS. The ability of the heme/BH4-
deficient nNOS mutant to inhibit CCK-induced stim-
ulation of NOS activity and cell proliferation as well
as CCK-induced nNOS dimers formation suggests
that nNOS may be required to mediate the effect of
CCK. As previously demonstrated, dimerization of
nNOS requires heme and BH4 (14, 26). Thus dimer-
ization of the nNOS mutant could not be observed
after its transfection in CHO cells. However, het-
erodimerization between mutant and wild-type
nNOS did not occur. We hypothesized that the
inactive nNOS could act as a competitive inhibitor of
endogenous nNOS regarding the transduction path-
way molecules activated by CCK such as tyrosine
phosphatase SHP-2.
Neuronal NO synthase displays a widespread ex-
pression in central and peripheral nervous systems
such as the gut and urogenital tract (27). This
isoform is considered to be responsible for the
largest proportion of tissue NO synthase activity. The
enzyme has thus been implicated in the regulation of
neuronal cell biology and in neuroendocrine biology
as a major nonadrenergic noncholinergic neuro-
transmitter in enteric nerves in the contraction of
skeletal muscle and relaxation of smooth muscle,
among other roles (28). Many authors speculate that
nNOS may be implicated in nervous system morpho-
genesis, neuronal differentiation, and synaptogen-
esis. Targeted disruption of the nNOS in mice by
homologous recombination did not reveal major
abnormalities of central nervous development (29).
Some authors have approached the role of nNOS in
cell growth or differentiation by investigating the
expression of the isoform on neuronal or phaeo-
Figure 10. SHP-2 associates to G-b1 subunit and nNOS CHO-K1
cells treated with CCK. A) CHO cells were plated in aMEM
containing 10% FCS until subconfluence and were treated or not
(after an 18 h period of serum deprivation) for the indicated times
with 0.1 mM CCK-8. Cell were subjected to immunoprecipitation
(i.p.) with anti-SHP-2 antibody; immune complexes were fraction-
ated by a 10% or 7.5% SDS-PAGE and subjected to sequential
immunoblotting with antibodies directed against G-b1 subunit
(blot: b1) or nNOS (blot: nNOS) (Fig. 8A). Arrows indicate the
positions of the G-b1 subunit and of nNOS. Filters were reprobed
with anti-SHP-2 antibodies (blot: SHP-2). After immunoprecipita-
tion with preimmune serum, followed by immunoblotting with
SHP-2 antibodies, no specific signal could be obtained (data not
shown). B) Immunoblots were densitometrically analyzed and data
were plotted as a percentage of control values from cells at time 0
(open bars: blot b1; hatched bars: blot nNOS). Data are from three
separate experiments and represented as mean 6 se.
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chromocytoma cells. Neuronal NOS has been in-
duced by growth factors or expressed in surviving
neurons (30). In addition, induction of different
isoform of NOS in phaeochromocytoma cells has
been responsible for growth arrest (31). During
Drosophila development, high expression of NOS and
the resulting NO production were responsible for
cell growth arrest (32). To our knowledge, however,
direct evidence of the implication of nNOS in the
positive regulation of cell proliferation of eukaryotic
cells has rarely been observed.
The physiological relevance of the coupling of
CCK receptor with nNOS remains to be established.
The mouse exocrine pancreas represents a tissue
model that expresses only the CCKA receptor sub-
type, as we found in our CHO-K1 strain. CCK is
known to stimulate exocrine pancreatic secretion
and growth in mice. NO is known to positively
modulate basal and stimulated exocrine pancreatic
secretion and blood flow in rodents. However, con-
troversies still exist in the possible direct implication
of the NO/cGMP system on amylase secretion by
acinar cells (33). Interestingly, we found that CCK-8
evoked a time-dependent stimulation of NOS activity
on mouse acinar cells and that nNOS was expressed
in pancreatic acinar cells (unpublished results). Ac-
tivation of nNOS could thus be implicated in the
mitogenic effect of CCK on exocrine pancreas. The
involvement of the coupling between CCKA recep-
tors and nNOS in the other biological effects of CCK
that implicate NO, such as relaxation of sphincter of
Oddi and lower esophagus, colonic, or gastroduode-
nal motility, and gastroprotection, remain to be
investigated.
Activation of nNOS requires activation of the
tyrosine phosphatase SHP-2 and G-bg subunit
The SH2-containing phosphotyrosine phosphatases
such as SHP-1 and SHP-2 regulate various protein
tyrosine kinase signaling pathways, interacting with
receptor autophosphorylation or with signaling pro-
teins. Whereas SHP-1 appears to be a negative regu-
lator of growth factors receptor signaling, SHP-2 is a
positive mediator of the mitogenic signaling induced
by several growth factors (19, 34). Many of these
growth factors act through receptors that possess an
intrinsic tyrosine kinase activity such as insulin,
PDGF, EGF receptors, but also act though G-protein-
coupled receptors such as thrombin or proteinase-
activated receptor 2 receptors (11, 35).
We observed that CHO cell proliferation induced
by CCK was dependent on a tyrosine phosphatase
and required the stimulation of SHP-2 activity. The
kinetic of activation of SHP-2 correlated well with
that of stimulation of NOS activity, dephosphoryla-
tion of nNOS on tyrosine residues, and association of
SHP-2 with nNOS evoked by CCK treatment. Expres-
sion of inactive SHP-2 inhibited CCK-induced cell
proliferation, nNOS dephosphorylation on tyrosine
residues, and NOS activity. As previously observed
(11, 36), this catalytically inactive protein can bind to
substrates without dephosphorylating them, thereby
competitively interfering with the access of these
substrates to the endogenous wild-type SHP-2. In the
present work, nNOS could thus be a substrate of
SHP-2. Taken together, these results suggest that
CCK treatment led to the activation of SHP-2 that
can dephosphorylate and then activate the nNOS.
The mechanism of association of SHP-2 with
nNOS and the tyrosyl residue involved on nNOS
remain to be identified. Nevertheless, this is the first
evidence that nNOS activity can be regulated by
tyrosine dephosphorylation. Using kinase or phos-
phatase inhibitors, the eNOS isoform has been
found to be regulated by phosphorylation on serine
threonine or tyrosine residues, but from indirect
observations (9, 37). Tyrosine phosphorylation also
seems to regulate association of eNOS with caveo-
lin-1 within endothelial caveola. Tyrosine phosphor-
ylation thus may regulate activity and subcellular
trafficking of eNOS (18). It has recently been sug-
gested that phosphorylation/dephosphorylation may
alter conformation and/or protein coupling of con-
stitutive NOS, facilitating their interactions with spe-
cific phospholipids or proteins that enhance or
maintain a Ca21-independent activation (38, 39).
Expanding examples of cellular responses regu-
lated by Gbg have already been described. Cell
growth and differentiation could implicate a or Gbg
protein subunits. In the present work, we observed
that the recombinant Gb1g2 subunit could induce a
stimulation of NOS activity. In addition, in the
expression of the carboxyl terminus of b-adrenergic
receptor kinase-1, a Gbg subunit-sequestering agent
inhibited the CCK-induced stimulation of SHP-2
activity, NOS activity, and cell proliferation. These
results also suggested that CCK stimulated SHP-2
activity in CHO cells via a Gbg-dependent pathway.
The kinetic of G-b1 and SHP-2 associations corre-
lated well with those of CCK-induced stimulation of
SHP-2 activity, CCK-induced stimulation of NOS
activity, and CCK-induced dephosphorylation of
nNOS on tyrosine residues. All these observations
suggest that upon CCK stimulation, the occupation
of CCKA receptors induced the recruitment of G-bg
subunit to SHP-2, which was activated and then
recruited nNOS to dephosphorylate and activate it.
In conclusion, the new concept of nNOS acting
as an important molecule in the signal cascade of
growth factors may have some practical implica-
tion taking into account the wide distribution of
this isoform both in neuronal and nonneuronal
tissues. Moreover, activation of nNOS by dephos-
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phorylation could be involved in other physiolog-
ical roles of nNOS in epithelial, neuronal, or
vascular systems.
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